EyeBio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 39

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $3.04B

EyeBio General Information

Description

Operator of an ophthalmology biotechnology company designed to develop vision therapy to protect, restore, and improve vision. The company protects against sight-threatening eye diseases, and introduced the first anti-vascular endothelial growth factor therapy for patients with age-related macular degeneration, enabling people with eye diseases to restore their vision.

Contact Information

Website
www.eyebiotech.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • International Building
  • 71 Kingsway
  • London WC2B 6ST
  • England, United Kingdom
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Acquirer
Merck & Co.
Vertical(s)
Life Sciences
Corporate Office
  • International Building
  • 71 Kingsway
  • London WC2B 6ST
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EyeBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 11-Jul-2024 $3.04B Completed Clinical Trials - General
1. Early Stage VC (Series A) 14-Nov-2023 Completed Clinical Trials - General
To view EyeBio’s complete valuation and funding history, request access »

EyeBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of an ophthalmology biotechnology company designed to develop vision therapy to protect, restore, and improve v
Drug Delivery
London, United Kingdom
39 As of 2024

Cambridge, United Kingdom
 

Ann Arbor, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EyeBio Competitors (4)

One of EyeBio’s 4 competitors is Exonate, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exonate Venture Capital-Backed Cambridge, United Kingdom
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
Gyroscope Formerly VC-backed London, United Kingdom
PulseSight Therapeutics Venture Capital-Backed Paris, France
To view EyeBio’s complete competitors history, request access »

EyeBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EyeBio Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bain Capital Life Sciences Corporate Venture Capital Minority
Gershon Capital Venture Capital Minority
Jeito Growth/Expansion Minority
MRL Ventures Fund Corporate Venture Capital Minority
Omega Funds Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Ready to get started?

Request a free trial

EyeBio FAQs

  • When was EyeBio founded?

    EyeBio was founded in 2021.

  • Where is EyeBio headquartered?

    EyeBio is headquartered in London, United Kingdom.

  • What is the size of EyeBio?

    EyeBio has 39 total employees.

  • What industry is EyeBio in?

    EyeBio’s primary industry is Drug Delivery.

  • Is EyeBio a private or public company?

    EyeBio is a Private company.

  • What is the current valuation of EyeBio?

    The current valuation of EyeBio is .

  • What is EyeBio’s current revenue?

    The current revenue for EyeBio is .

  • How much funding has EyeBio raised over time?

    EyeBio has raised $130M.

  • Who are EyeBio’s investors?

    Bain Capital Life Sciences, Gershon Capital, Jeito, MRL Ventures Fund, and Omega Funds are 5 of 8 investors who have invested in EyeBio.

  • Who are EyeBio’s competitors?

    Exonate, ONL Therapeutics, Gyroscope, and PulseSight Therapeutics are competitors of EyeBio.

  • When was EyeBio acquired?

    EyeBio was acquired on 11-Jul-2024.

  • Who acquired EyeBio?

    EyeBio was acquired by Merck & Co..

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »